Universal access to drug susceptibility testing for newly diagnosed tuberculosis patients is recommended. Access to culture-based diagnostics remains limited, and targeted molecular assays are vulnerable to emerging resistance mutations.
Journal article
Journal of Clinical Microbiology
American Society for Microbiology
23/03/2023
61